Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17192652 | 1.00 | GRM4 (0.54) | GRM4ALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL13538882 | 1.00 | GRM4 (0.54) | GRM4ALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL5909473 | 0.91 | GRM4 (0.56) | GRM4ALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL13544810 | 0.82 | GRM4 (0.50) | GRM4ALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL9017695 | 0.80 | EPHX1 (0.54) | GRM4ALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL150817 | 0.80 | PEPD (0.54) | GRM4ALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL1680973 | 0.80 | PEPD (0.54) | GRM4ALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL4818635 | 0.80 | PEPD (0.54) | GRM4ALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL1805083 | 0.80 | PEPD (0.54) | GRM4ALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL38660911 | 0.80 | PEPD (0.54) | GRM4ALDH1A1LMNAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4139295-B1 | ISOQUINILINE NRF2 AGONISTS | C4X DISCOVERY LTD (GB) | 2025-04-09 | — | — | EP | disclosed |
| CN-115667242-B | Tetrahydroisoquinoline compounds as NRF2 activators | 希四克斯探索有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20230159511-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | C4X DISCOVERY LIMITED (GB) | 2023-05-25 | — | — | US | disclosed |
| EP-4139295-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | C4x Discovery Limited (GB) | 2023-03-01 | — | — | EP | disclosed |
| CN-115667242-A | Tetrahydroisoquinoline compounds as NRF2 activators | 希四克斯探索有限公司 | 2023-01-31 | — | — | CN | disclosed |
| WO-2021214472-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | C4X DISCOVERY LIMITED (GB) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159511-A1 | TETRAHYDROISOQUINOLINE COMPOUNDS AS NRF2 ACTIVATORS | NFE2L2, KEAP1, NQO1 | GRM4 2818/4885ALDH1A1 773/4885LMNA 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.